AB
DSGN icon

Amalgamated Bank’s Design Therapeutics DSGN Stock Holding History

Amalgamated Bank’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-751
Closed -$7K – 1967
2025
Q4 		$7K Sell
751
-425
-36% -$3.33K ﹤0.01% 2569
2025
Q3 		$9K Hold
1,176
– – ﹤0.01% 2509
2025
Q2 		$4K Hold
1,176
– – ﹤0.01% 2828
2025
Q1 		$5K Hold
1,176
– – ﹤0.01% 2646
2024
Q4 		$7K Hold
1,176
– – ﹤0.01% 2590
2024
Q3 		$6K Hold
1,176
– – ﹤0.01% 2682
2024
Q2 		$4K Hold
1,176
– – ﹤0.01% 2841
2024
Q1 		$5K Sell
1,176
-1,754
-60% -$4.68K ﹤0.01% 2706
2023
Q4 		$8K Sell
2,930
-350
-11% -$802 ﹤0.01% 2892
2023
Q3 		$8K Hold
3,280
– – ﹤0.01% 2928
2023
Q2 		$21K Sell
3,280
-226
-6% -$1.38K ﹤0.01% 2705
2023
Q1 		$20K Sell
3,506
-785
-18% -$5.87K ﹤0.01% 2643
2022
Q4 		$44K Hold
4,291
– – ﹤0.01% 2476
2022
Q3 		$72K Hold
4,291
– – ﹤0.01% 2301
2022
Q2 		$60K Buy
4,291
+420
+11% +$5.67K ﹤0.01% 2389
2022
Q1 		$63K Buy
+3,871
New +$59.3K ﹤0.01% 2360

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Amalgamated Bank's DSGN Position: Q1 2026 in Review

Amalgamated Bank sold out of Design Therapeutics (DSGN) in Q1 2026, closing a stake of 751 shares — an estimated $7K sold.

Amalgamated Bank first reported a position in DSGN in Q1 2022 and held it in 16 quarters. The position peaked at $72K in Q3 2022. 125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

  • Amalgamated Bank reported no remaining Design Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 751 Design Therapeutics shares in Q1 2026, an estimated $7K.
  • Amalgamated Bank first reported a position in Design Therapeutics in Q1 2022 and held it in 16 quarters.
  • Amalgamated Bank's Design Therapeutics position peaked at $72K in Q3 2022.
  • 125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.